NeoGenomics, Inc. Q2 FY2025 earnings call

• Tony Zook, CEO, discussed his first quarter as CEO, emphasizing reexamining strategic initiatives and financial targets. Acknowledged delivery below expectations but remains optimistic, focusing on execution excellence.
• Clinical business had solid performance with volume and share gains in key segments, but nonclinical revenue was below expectations.
• Launched PanTracer liquid biopsy commercially, delayed due to learning from EAP to improve product profile.
• Updates on pharma macro environment impacting revenue, including NIH funding, drug pricing, tariffs; investments in operating efficiencies like LIMS integration and digital pathology.
• Pathline acquisition is on track, and strategic drivers focus on customer experience, community channel, and new products (e.g., MRD and therapy selection NGS).

Total revenue for Q2 was $181 million, up 10% year-over-year. Total clinical revenue increased 16% year-over-year, with organic clinical revenue at $160 million, a 13% growth driven by a 10% increase in test volumes and 3% increase in AUP. NGS testing accounted for 32% of total clinical revenue and grew 23% year-over-year. Nonclinical revenue was down 26% year-over-year due to weakness in pharma revenue.

• Revised 2025 revenue guidance to $720 million to $726 million, 9%-10% growth, with adjusted EBITDA $41 million to $44 million. Delayed PanTracer launch and pharma macro environment headwinds contributed to guidance change.
• Confident in long-range plan with core business growth (10%+), business development adding incremental revenue, and new product launches (e.g., PanTracer, next-gen MRD) driving incremental revenue.

• Pharma macro environment uncertainties including NIH funding declines, drug pricing challenges, tariffs affecting pharma revenue.
• Delayed launch of PanTracer liquid biopsy impacting revenue mix.
• Litigation risks related to RaDaR RD, including Natera's motion for bench trial and slated October trial.

Q: Andrew Brackmann from William Blair asked about the process and philosophy for setting guidance and rebuilding investor credibility.

A: Tony Zook discussed learning from being CEO, with pharma macro environment and PanTracer launch delay impacting guidance, and focus on delivering and regaining investor confidence.

Q: Yuko Oku from Morgan Stanley asked about portfolio pruning and balancing one-stop shop vs. profitable products.

A: Tony Zook and Warren Stone discussed leveraging PanTracer's competitive profile, broad portfolio strength, and ongoing evaluation of portfolio for profitability.

Q: Thomas VonDerVellen from Guggenheim Securities asked about second half ramp and guide risks.

A: Tony Zook discussed pharma risks as largest guide risk, with sales force investment, PanTracer launch, Adaptive partnership, and Pathline integration driving second half growth.

Q: Michael Matson from Needham & Company asked about long-range plan and nonclinical business.

A: Tony Zook clarified long-range plan focus on anchor 10% growth, with nonclinical business having synergies but short-term impact reflected in guidance.

Q: Dan Brennan from TD Securities asked about nonclinical business and MRD strategy.

A: Jeff Sherman and Tony Zook discussed nonclinical business performance, MRD litigation, and Adaptive partnership for Heme MRD.